420 with CNW — Ohio Campaigners Start Effort to Undo Recent Changes to State Marijuana Laws

A new campaign is underway to challenge recent changes to Ohio’s cannabis laws, setting the stage for another statewide vote on cannabis policy. Ohioans for Cannabis Choice has launched a referendum effort aimed at overturning parts of Senate Bill 56, legislation that tightens rules around intoxicating hemp products and revises the recreational cannabis framework approved by voters in 2023.

If the effort succeeds, the question of whether to repeal portions of the law would appear on the statewide ballot next November. To reach the ballot, organizers must gather close to 250,000 valid signatures, a process that is already moving forward.

Supporters say the new law undermines what voters endorsed when they approved adult-use marijuana. Since that election, lawmakers have repeatedly revisited the cannabis statute, arguing that technical fixes and public safety concerns made revisions necessary. Critics counter that the legislature went far beyond clarification.

SB 56 establishes limits on cannabis potency, restricts smoking in many public areas, and creates penalties for consuming cannabis inside vehicles, whether someone is driving or riding along. It also bars residents from bringing legally purchased cannabis into Ohio from other states and sets criminal consequences for exceeding limits on home cultivation. Provisions protecting cannabis users from discrimination in housing, employment, and organ donation were also removed.

Under the new rules, hemp-derived products that cause intoxication would be allowed only within licensed marijuana dispensaries. Supporters of the change say it aligns Ohio law with updated federal standards.

Governor Mike DeWine has repeatedly criticized the spread of hemp-based edibles and beverages, especially products packaged to resemble familiar candy or snack brands. With his signature on SB 56, most of these products will be illegal come March.

While lawmakers initially included language allowing low-dose THC beverages to remain legal until federal rules change in 2026, DeWine removed that provision through a line-item veto, effectively ending their sale at the same time.

The referendum campaign began immediately after the bill became law, with initial paperwork and signatures filed within days. State officials now have limited time to verify signatures and review the petition language. If approved, organizers will have 90 days to gather the remaining signatures, including minimum thresholds in at least half of Ohio’s counties.

State Senator Steve Huffman, the bill’s sponsor, acknowledged frustration from some voters but said the legislation mainly clarified ambiguities. He cited homegrow limits as an example, arguing that lawmakers aligned the statute with what voters intended. Huffman also said lawmakers improved expungement procedures and worked to simplify licensing for businesses.

He questioned whether the referendum truly reflects voter concerns, suggesting opposition is largely driven by hemp industry interests. DeWine’s office echoed that view, saying the 2023 ballot measure did not guarantee the right to sell THC products in bars or convenience stores. While affirming the public’s right to pursue a referendum, administration officials argue the campaign’s claims do not fully match the language voters approved.

The broader marijuana industry, including established entities like Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), will be keeping an eye on how the debate plays out and any regulatory changes that emerge in the state.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Trump’s Cannabis Order Injects New Life into Hemp Industry

President Trump has offered a boost to the struggling hemp sector with his executive order that directs federal agencies to accelerate the reclassification of cannabis and explore Medicare coverage for CBD products. The move arrives as the industry prepares for a major policy fight in Congress over rules that could sharply restrict hemp-derived goods.

The sector has faced mounting pressure since November, when lawmakers inserted new language into a government funding package aimed at tightening oversight of hemp-derived products. The provision was designed to close a regulatory gap that allowed hemp products to be sold widely with limited federal scrutiny. Industry representatives argue the change goes too far and could effectively wipe out much of the consumer CBD market.

The executive order, signed last week, signals a shift in tone at the federal level. It followed sustained lobbying by cannabis advocates, including some with longstanding ties to the president. While the order does not alter the law, it calls on administration officials to collaborate with Congress to revise existing statutes, allowing certain CBD products to remain available while addressing those that pose legitimate health concerns.

Hemp-derived CBD remains legal, and hemp is not classified as a controlled substance. Still, industry leaders say the president’s directive gives them political momentum. U.S. Hemp Roundtable general counsel Jonathan Miller described the order as a clear rejection of the restrictive language adopted in the funding bill. He added that it strengthens the industry’s position as lawmakers revisit the issue over the coming months.

Hemp was legalized through the 2018 Farm Bill, originally envisioned for uses such as farming and manufacturing. However, broad statutory definitions and limited oversight allowed some producers to concentrate or chemically alter THC derived from hemp, resulting in products that critics say can be just as potent as marijuana.

The funding bill includes a one-year delay before the new limits take effect, giving companies time to press for changes. Thomas Winstanley, an executive at Edibles.com, said businesses are seeking at least an additional six months ahead of the January 30 funding deadline, hoping lawmakers will adjust the policy.

Some advocates caution that the administration’s support is narrowly focused. The order directs the attorney general to move faster on shifting marijuana from Schedule I, reserved for substances with no accepted medical use, to Schedule III, which includes most prescription medications. That change would not protect companies selling synthetic or highly intoxicating THC products under the hemp label.

Chris Lindsey of the American Trade Association for Cannabis & Hemp said the intent is to carve out space for legitimate CBD producers, not businesses operating like marijuana retailers. He argued that the current definition is so sweeping that it risks blocking lawful products from the market. In his view, the president’s message to Congress is to revisit the language and ensure responsible CBD companies are not caught in the dragnet.

As the regulatory landscape for hemp and marijuana evolves over the coming months, firms like Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) will be keeping tabs to analyze how the new regulations impact their business projections.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — As Federal Drug Policy Evolves, Tennessee Lawmakers Mull Medical Marijuana Reforms

Cannabis has been removed from the federal government’s most restrictive drug category following a recent executive order by President Donald Trump. The move shifts marijuana from Schedule I, a group reserved for substances deemed to have no accepted medical use, to Schedule III.

While the change marks a significant shift in federal policy, its impact in Tennessee remains uncertain, especially as the state prepares to implement stricter cannabis-related laws.

Tennessee remains among the ten states that prohibit marijuana entirely, including both medical and recreational use. That stance will be reinforced on January 1, when a new state law takes effect regulating hemp-derived products and prohibiting specific forms of THCA. The law is intended to tighten oversight of products currently sold in stores across the state.

The new order broadens opportunities for scientific research into medical cannabis. During the signing, President Trump said the change responds to decades of requests from patients coping with severe and ongoing pain.

Despite the state’s firm position, the federal reclassification has reopened debate among Tennessee lawmakers. Some Republican legislators say they are willing to revisit the issue of medical marijuana if future studies demonstrate clear benefits.

State Senator Heidi Campbell welcomed the federal decision and urged Tennessee leaders to follow suit. She stated that the state has lagged behind national trends and argued that policy should reflect the evolving scientific understanding and the needs of patients.

Some have expressed cautious openness. House Speaker William Lamberth said any adjustments to state law would depend on credible evidence showing legitimate medical use. He emphasized the importance of building laws around solid research when dealing with substances that carry risks.

Senator Mark Pody echoed a similar sentiment, noting that medical cannabis could potentially address health concerns while also reducing incarceration rates linked to drug offenses.

Personal stories are also shaping the conversation. Billy Reichardt, who grew up in Hendersonville and now lives in Florida, said he turned to medical cannabis after years of chronic neck and back pain.

He credits cannabis with easing both his physical discomfort and anxiety. Reichardt said he would like to see similar access in Tennessee, arguing that regulated medical use could help patients while also generating tax revenue and improving oversight.

Not all state leaders agree. Lieutenant Governor Randy McNally has maintained that cannabis remains dangerous and has said he does not believe it offers meaningful medical value.

For now, Tennessee’s cannabis laws remain unchanged. However, with federal policy shifting and lawmakers signaling renewed interest, the issue is expected to resurface when the legislature reconvenes. Whether that discussion leads to reform or reinforces the state’s current approach remains to be seen.

Cannabis firms like Tilray Brands Inc. (NASDAQ: TLRY) (TSX: TLRY) will be tracking the debates around the U.S. in the wake of the federal change to the classification of marijuana to see whether the new development triggers broader drug policy reforms.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — GOP State AGs Oppose Trump’s Plan to Reschedule Marijuana

A group of GOP state attorneys general is pushing back against President Donald Trump’s move to reclassify cannabis, arguing that marijuana should remain among the most tightly controlled substances due to health and safety concerns.

In a recently released joint statement, AGs from Iowa, Indiana, Idaho, Louisiana, Kansas, Nebraska, Wyoming, and Oklahoma said they have long rejected calls to loosen federal restrictions on marijuana and believe recent scientific findings reinforce their position.

They also pointed to what they described as real-world consequences of wider marijuana access, citing damage they say the drug has caused in their states. Among their concerns is what they described as a sharp rise in impaired driving cases, which they said are difficult for law enforcement to detect and prosecute.

The group noted that its members had shared their objections with the White House and expressed appreciation for what they described as the administration’s willingness to listen. Still, they said they are troubled by the executive order directing the U.S. Attorney General to move forward with the rulemaking process to place cannabis in Schedule III.

They added that they plan to closely review the order and consider next steps, emphasizing their intent to protect public health and ensure community safety.

In a separate announcement, South Dakota AG Marty Jackley said he and other attorneys general participated in a conference call with White House officials to discuss the executive order following the president’s signing event. Jackley said he appreciated what he described as ongoing communication between the administration and state law enforcement leaders.

Jackley also stressed that reclassifying marijuana would not amount to nationwide legalization. He noted that federal law would still prohibit marijuana from being prescribed by doctors unless it receives approval from the Food and Drug Administration. In South Dakota, he said, recreational use would remain illegal, and medical use would continue to be allowed only under strict conditions, including a valid prescription, a medical card, and purchases from licensed facilities.

The attorneys general’s criticism comes after GOP legislators in the House and Senate sent letters to Trump urging him to abandon plans to reclassify marijuana. Trump publicly brushed aside those objections, arguing that most Americans favor the policy shift and that cannabis has helped people dealing with serious medical conditions. He also referenced friends of his own who, he said, had benefited from its use.

While the proposed change would not make marijuana legal at the federal level, it would have significant practical effects. It would allow state-licensed marijuana businesses to claim standard federal tax deductions under Section 280E of the Internal Revenue Code. The change would also ease restrictions on scientific research, making it simpler for researchers to study marijuana compared with drugs that remain in Schedule I.

The opposition from sections of the GOP notwithstanding, the long-awaited change to the classification of marijuana at the federal level could improve the conditions under which marijuana companies operate at state level, and that would in turn open up new opportunities for companies similar to Innovative Industrial Properties Inc. (NYSE: IIPR) to be created to serve within the marijuana ecosystem.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

CannabisNewsBreaks – Golden Triangle Ventures Inc. (OTC: GTVH) Establishes Snapt Beverages as Vertically Integrated Manufacturing and Brand Platform

Golden Triangle Ventures (OTC: GTVH) (“GTV”) announced the establishment of Snapt Beverages as its manufacturing and brand development division, operating as a wholly owned subsidiary and strengthening the Company’s foundation as a vertically integrated consumer products platform built for scale. The Company has closed on and taken control of its fully operational 11,000-square-foot Florida manufacturing facility, which is actively producing across multiple beverage categories, including functional beverages, energy drinks, hydration products, hydrogen water and THC/CBD-infused beverages, while supporting quality assurance, packaging, warehousing and logistics coordination. Through Snapt Beverages, Golden Triangle Ventures now operates a fully integrated, in-house manufacturing platform delivering immediate production activity, existing customer demand and recurring cash flow, while supporting internal brands such as Go Fast Sports & Beverage and external partners through formulation, branding, manufacturing, packaging and launch execution, creating a scalable foundation for national retail expansion beginning in 2026 and long-term shareholder value growth.

To view the full press release, visit https://cnw.fm/WFhTc

About Golden Triangle Ventures, Inc.

Golden Triangle Ventures (OTC: GTVH) is a diversified company developing a portfolio of high-growth businesses across construction, energy, and consumer goods. Through subsidiaries such as GoldenEra Development, GoFast Sports, Deep South Electrical Contractors, and its future Manufacturing & Logistics Division, the company operates a vertically integrated model focused on profitability, innovation, and long-term shareholder value.

NOTE TO INVESTORS: The latest news and updates relating to GTVH are available in the company’s newsroom at https://cnw.fm/GTVH

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Austin, Texas
www.CannabisNewsWire.com
512.354.7000 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Trump Signs Order Expediting Federal Marijuana Rescheduling

President Donald Trump has signed an executive order that would expedite cannabis rescheduling, easing restrictions that have been in place for more than half a century.

The order focuses on speeding up an ongoing review under the Controlled Substances Act, the federal framework that sorts drugs into five categories based on medical usefulness and abuse potential.

At the top of that system is Schedule I, reserved for substances deemed highly addictive, dangerous, and lacking any accepted medical benefit. Cannabis has remained in that category since 1970, grouped with drugs such as heroin. At the opposite end is Schedule V, which includes medications considered to have clear medical value and low risk of misuse.

Placement in Schedule I has long created barriers for scientists seeking to study cannabis. Researchers face additional licensing requirements, limits on supply, and other regulatory obstacles that do not apply to substances in lower schedules. This has frustrated doctors and patients who point to decades of use of cannabis-based treatments for conditions such as chronic pain, nausea, and muscle spasms.

Reclassification efforts began under President Joe Biden, who in 2022 asked the Department of Health and Human Services and the Department of Justice to review marijuana’s placement. At the time, Biden argued that treating cannabis more harshly than drugs like methamphetamine and fentanyl did not align with scientific evidence or public health realities.

The review moved forward in 2023 when the DHHS recommended moving cannabis to Schedule III. Drugs in this category are recognized as having medical value and a moderate to low likelihood of abuse. Acting on the recommendation, the DOJ released a proposed rule in 2024, opening the door for public comment.

Roughly 43,000 responses were submitted, and about 70% supported changes that went beyond rescheduling, including removing marijuana from the controlled substances list entirely or legalizing it nationwide. The proposal is now headed toward an administrative hearing.

If approved, the change would mark an unprecedented shift as federal authorities have never reclassified a Schedule I substance that is as widely used as cannabis. It is currently legal for medical purposes in 40 states and Washington, DC, while recreational use is permitted in 24 states. Surveys also show that daily cannabis consumption now exceeds similar patterns of alcohol use among American adults.

While the executive order does not immediately change marijuana’s legal status, it instructs the DOJ to complete the ongoing rulemaking as quickly as federal law allows. Lawmakers could also act independently, since Congress has the authority to amend the Controlled Substances Act.

For now, the order signals renewed momentum in a debate that has steadily reshaped drug policy across the United States. Local and foreign based marijuana companies like Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) will be closely following how the administrative review process pans out and the final rule enacted.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — E-Commerce is Helping to Normalize Marijuana in the US

Imagine scrolling through an article about a newly released marijuana strain or infused drink, spotting a purchase link, and reserving the product for same-day pickup at a nearby licensed dispensary. That scenario, once unlikely in the cannabis sector, is moving closer to everyday retail reality.

Consumers at licensed marijuana stores are beginning to see this shift through a new partnership between High Times, a long-running cannabis publication, and Hoodie Analytics, a Chicago-based data and technology company. The collaboration combines editorial content with an online ordering system, enabling readers nationwide to search for legal products, place a reservation, and complete the purchase in person at approved retailers.

Transactions are still finalized face-to-face, keeping the process aligned with state laws. Even so, the experience closely mirrors how customers shop for many other regulated products online.

Industry leaders say the effort responds to long-standing frustrations among brands and retailers. Wes Shepherd, CEO of Hoodie Analytics, said many businesses struggle with how consumers discover products. He believes the current system makes it difficult for shoppers to find what they want without relying heavily on discounts or promotions.

Unlike existing cannabis marketplaces, the High Times platform allows readers to move directly from an article to a product listing through embedded links. Matt Stang, a partner at High Times, said the model benefits retailers by sending qualified customers their way while keeping the shopping process simple.

Hoodie’s database tracks over 10,000 licensed stores and roughly 9 million individual product listings across the United States. Retailers can also join Hoodie Connect, a no-cost program that offers additional visibility and order referrals through High Times’ audience.

Not everyone is convinced that e-commerce will benefit all brands equally. Dialed In Gummies President Max Vansluys noted that premium producers can struggle in online environments where lower-priced options dominate. He argued that in-store guidance matters, especially for customers unfamiliar with quality differences. Budtenders, he said, play a critical role in helping shoppers understand why a product costs more.

Vansluys added that once an order is placed online, the interaction can become purely transactional. Without personal guidance, consumers may default to cheaper options rather than better ones. Still, he acknowledged benefits, particularly for travelers who want to locate familiar products when visiting another state.

Former LivWell and PharmaCann Executive Chris Mapson echoed that point, noting that cannabis remains highly regional. He said the platform allows readers to quickly see whether a product mentioned in an article is sold in their area.

Beyond digital commerce, High Times is also investing in print. Through a partnership with Colorado-based Cannapages, the company plans to launch High Times Local, a city-specific magazine featuring coupons, advertising, and local coverage. The first editions are set to appear in Phoenix, Denver, and Colorado Springs, with more cities planned for next year.

Cannapages’ Matt Hollingshead said physical publications still resonate with readers. Stang added that younger audiences, much like music fans returning to vinyl, are showing renewed interest in tangible media they see as authentic and lasting.

These developments in cannabis marketing are likely to be of interest to established companies like Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED) as they could open new avenues to drive sales.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Study Suggests Legalizing Marijuana Lowers Suicide Rates Among Seniors

States that allowed recreational marijuana stores to open experienced a drop in suicide rates among older residents, according to a recent analysis that reviewed more than twenty years of data from across the U.S. The findings suggest a clear association between the start of legal cannabis sales and a measurable decline in suicides among adults later in life.

The study analyzed monthly suicide figures from all 50 states. The goal was to examine whether expanded access to cannabis, specifically through regulated retail outlets, had any observable connection to mental health.

The researchers found that suicide rates fell among people aged 45 and over in states with recreational marijuana stores. The decline was most noticeable among men, a group that has long had higher rates of suicide than women. Men in this age range are also likely to report using cannabis to cope with chronic pain, which is a known contributor to depression and suicide risk.

The analysis did not show similar changes among younger people. It also found no reduction in suicide rates in states that legalized adult-use marijuana but had yet to open retail locations. According to the authors, this distinction points to access rather than cannabis legalization on paper as the key factor.

The study found no evidence that expanded marijuana availability led to an increase in suicides. This runs counter to concerns raised by critics of legalization, who have warned that broader cannabis use could worsen mental health, particularly among younger adults.

The paper also addressed the broader factors that contribute to suicide risk, pointing to pain management as an area that has received limited attention in previous research. They argue that understanding how cannabis may alleviate underlying physical discomfort adds a new dimension to debates over marijuana policy.

To rule out other explanations, the researchers accounted for a range of additional policies and economic factors. Their analysis included alcohol and tobacco taxes, as well as several opioid-related measures such as prescription limits, pill mill regulations, and drug monitoring programs. None of these factors explained the decline they observed.

The findings come amid ongoing concern over the rate of suicide in the United States, which remains close to record levels, particularly among senior and middle-aged adults. While the reduction associated with cannabis dispensaries was relatively small, the researchers emphasize that even incremental improvements can translate into lives saved when applied across large populations.

The authors cautioned that more research is needed to understand why the association exists and how cannabis use may influence mental health in different groups. Entities like TerrAscend Corp. (TSX: TSND) (OTCQX: TSNDF) operating licensed marijuana outlets will be glad that their products could be having such unintended positive effects on their users and potentially saving lives.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Marijuana Derivatives Show Promise in Treating Ovarian Cancer

Researchers searching for better ways to treat ovarian cancer have reported encouraging results from laboratory tests involving two marijuana compounds. According to a new study, both THC and CBD were able to slow the growth of ovarian cancer cells, and when used together, they were particularly effective at killing existing malignant cells.

The findings, published in the journal Frontiers in Pharmacology, are still at an early stage and are limited to cell-based studies. However, scientists say the results point to a possible new direction for therapies targeting a disease that is often detected late and remains difficult to manage with current drugs.

CBD, which does not produce a psychoactive effect, and THC, which does, have previously shown anti-cancer activity in studies involving other tumor types. Based on that evidence, the research team examined how both substances affected ovarian cancer cells grown in the laboratory.

The scientists worked with two types of ovarian cancer cells. One was responsive to platinum-based chemotherapy, while the other was resistant to it. Each cell line was exposed separately to CBD, THC, and a combination of the two. Healthy cells were also included to assess potential toxicity.

Results showed that cancer cells treated with either compound produced fewer colonies and displayed reduced growth. The strongest effects were observed when CBD and THC were applied together. While each substance alone had a limited ability to kill cancer cells outright, their combined use led to a significant increase in cancer cell death. Researchers believe the compounds may act through different biological processes that reinforce each other when paired.

Further tests revealed that treated cancer cells were less able to move, an important finding since the spread of cancer to other organs is a leading cause of death in ovarian cancer patients. If confirmed in further studies, this could mean the compounds help limit metastasis.

Notably, both chemotherapy-sensitive and resistant cancer cells reacted in similar ways. Healthy cells showed little change, raising the possibility that treatments based on these compounds might be easier to tolerate than current options.

To understand how the effects occur, the researchers examined a key cellular signaling system known as the PI3K/AKT/mTOR pathway, which is often overactive in ovarian tumors. THC and CBD appeared to bring this pathway back under control, reducing cancer cell growth and survival.

Despite the promising data, researchers caution that extensive additional studies are required. Animal testing and clinical trials will be necessary to determine safety, dosage, and real-world effectiveness. For now, the findings offer a potential foundation for future therapies aimed at improving outcomes for patients with ovarian cancer.

These findings come at a time when reports show President Trump is considering using an executive order to shift marijuana from Schedule I to III of the CSA. The wider marijuana industry, including enterprises like SNDL Inc. (NASDAQ: SNDL), welcomes these positive developments that could help to support efforts to reform drug policies around the world.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Trump to Sign Executive Order Rescheduling Marijuana

President Donald Trump is expected to announce a plan that could shift cannabis from Schedule I to Schedule III under federal drug law, a change that would, for the first time, formally acknowledge cannabis as having accepted medical use in the U.S.

If finalized, the move would represent one of the most consequential adjustments to federal marijuana policy in years. It could reshape how cannabis businesses are taxed, how medical marijuana is viewed within healthcare, and how federal agencies interact with a market that has long existed in legal gray areas. Still, the proposal stops well short of nationwide legalization and has sparked mixed reactions across the industry.

Under federal law, Schedule III drugs are considered to have accepted medical use and a lower likelihood of abuse than substances listed in Schedules I or II. This category includes drugs such as anabolic steroids, ketamine, and certain codeine-based pain medications.

The most immediate practical impact could come through the tax code. Businesses that deal in Schedule I or II substances are barred from deducting ordinary operating expenses under Internal Revenue Service rule 280E.

Industry executives say relief from this provision could significantly improve cash flow for licensed operators and make long-term investment more realistic. However, they caution that other obstacles, including limited access to banking services, would remain.

Supporters argue that Schedule III status would further legitimize medical marijuana and help integrate it into conventional healthcare systems. They say federal recognition could encourage research, standardization, and broader acceptance among doctors and patients.

Some industry leaders, however, are wary of unintended consequences. Some warn that shifting marijuana into a medical category could expose existing operators to new forms of federal liability. They caution that treating THC as a prescription substance could allow pharmaceutical companies to dominate the market with synthetic alternatives, while dispensaries and growers could face scrutiny under federal drug and consumer protection laws.

Advocates are divided on how the shift might affect social equity. Some believe formal recognition of medical use could draw more people into the legal market, including those from communities disproportionately harmed by past enforcement. Others worry it could widen the gap between well-funded companies and small, independent businesses.

Questions also remain about how rescheduling would align with ongoing debates over hemp-derived THC products. Joe Gerrity, chief executive of Crescent Canna, pointed to what he called a contradiction between easing marijuana rules while moving to restrict or eliminate hemp-based alternatives through future legislation. He said the change could either push lawmakers toward a clearer national policy or deepen existing confusion.

For many in the cannabis space, rescheduling would mark long-overdue acknowledgment after years of stigma. Still, there is broad agreement that the change, while historic, would not amount to full legalization. Without further action on insurance, banking, federal enforcement, and clear FDA pathways, both patients and businesses would continue to navigate a complex and uncertain system.

It remains to be seen how entities like Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF) will adjust their long-term strategies and operations in light of this expected executive order rescheduling marijuana federally.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com